Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration

Ophthalmologica

Volumn 230, Issue 1, 2013, Pages 27-33

  Muniraju, Ramu ^a   Ramu, Jayashree ^a   Sivaprasad, Sobha ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Injection frequency; Neovascular age related macular degeneration; Ranibizumab; Visual acuity

Indexed keywords

RANIBIZUMAB;

AGE; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; DRUG EFFICACY; EARLY TREATMENT DIABETIC RETINOPATHY STUDY CHART; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; VISION; VISUAL ACUITY; VISUAL ACUITY CHART; VISUAL IMPAIRMENT;

EID: 84879845100     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000350238     Document Type: Article

References (20)

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, Group AS: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
3. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL, Comparison of Age-Related Macular Degeneration Treatments Trials research group: Ranibizumab and bevacizumab for treatment of neovascular agerelated macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
4. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411.
5. Abraham P, Yue H, Wilson L: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010; 150: 315-324.
6. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, Group SS: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-671.
7. National Institute for Clinical Excellence: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. Technology Appraisals August 2008 (TA 155). http://www. nice.org.uk (accessed on January 29, 2013).
8. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prunte C, Schmidt-Erfurth U, Tano Y, Wolf S: Ranibizumab (Lucentis) in neovascular agerelated macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2-13.
9. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58.
10. Querques G, Azrya S, Martinelli D, Berboucha E, Feldman A, Pece A, Coscas G, Soubrane G, Souied EH: Ranibizumab for exudative agerelated macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010; 94: 292-296.
11. Bandukwala T, Muni RH, Schwartz C, Eng KT, Kertes P: Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. Can J Ophthalmol 2010; 45: 590-595.
12. Williams TA, Blyth CP: Outcome of ranibizumab treatment in neovascular age related macular degeneration in eyes with baseline visual acuity better than 6/12. Eye 2011; 25: 1617-1621.
13. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK: Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009; 116: 1740-1747.
14. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, Group MS: Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 246-252.
15. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR: Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144: 850-857.
16. Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J, Pujol O: One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina 2011; 31: 1261-1267.
17. Hjelmqvist L, Lindberg C, Kanulf P, Dahlgren H, Johansson I, Siewert A: One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol DOI: 10.1155/2011/405724.
18. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ, CATT research group: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
19. Kumar A, Sahni JN, Stangos AN, Campa C, Harding SP: Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol 2011; 95: 530-533.
20. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE: Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009; 147: 831-837.